Melt Extrusion

Techniques to overcome poor aqueous solubility of active pharmaceutical ingredients (APIs) continue to gain interest, with a reported 30% of marketed compounds classified as BCS II and 10% classified as BCS IV. Approximately 70% of new…

Croda announces the new Pharma business

Croda has announced that its Health Care division will now become Croda Pharma, bringing its core speciality excipient portfolio together with the recent acquisition, Avanti Polar Lipids and its Adjuvant Systems arm, all under one business.…

Croda

At Croda International Plc, we offer a vast portfolio of excipient solutions including specialised lipids, high purity speciality chemistries, and key functional ingredients which solve the challenges faced by pharmaceutical manufacturers…